Citations

Clear

623 citation(s) found for "Torres, V".

Expression of metabolic genes associated with changes in brain structure across the lifespan affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).
Millstein, Joshua , Yang, Yan , Algaze, Sandra , Ashouri, Karam , Wong, Alexandra , Lo, Jae Ho, Torres‐Gonzalez, Lesly , Zhang, Wu, Höchster, Howard S. , Innocenti, Federico , Lenz, Heinz‐Josef , Battaglin, Francesca , Yang, Yan , Soni, Shivani , Arai, Hiroyuki , Mittal, Pooja , Jayachandran, Priya , Ou, Fang‐Shu , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3144-3144

10.1200/jco.2024.42.16_suppl.3144 Get It

3144 Background: Longitudinal brain structure changes across the lifespan are associated with neurodegenerative disorders. We previously showed that genetic variants in dopamine and Parkinson’s disease genes are predictive and prognostic in mCRC. Indeed, the brain-gut axis is emerging as a critical player in CRC biology. Hence, we investigated whether the tumor gene expression of 3 metabolic genes involved in brain development and aging could affect treatment response in patients enrolled in the CALGB/SWOG 80405 trial. Methods: 433 mCRC pts treated with either bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) in combination with first-line chemotherapy were included in the analysis. RNA was isolated from FFPE tumor samples and sequenced on the HiSeq 2500 (Illumina). Overall survival (OS) and progression-free survival (PFS) were compared between groups of pts categorized by tertiles of expression of 3 genes: APOE, DACH1, and GPR139. Likelihood ratio tests, hazard ratios and 95% confidence intervals were computed from multivariate Cox proportional hazards models, adjusting for age, sex, ethnicity, ECOG PS, tumor location, number of metastatic sites, KRAS, MSI status, and treatment. Logrank P-values describe differences without adjustment for patient characteristics. Results: Both APOE and DACH1 (but not GPR139) met the 0.05 false discovery rate threshold for association with both PFS ( P = .00085, P = .015) and OS ( P = .021, P = .021, respectively) in the full Cox models. In cet-treated pts, APOE-high (H) showed significantly shorter PFS (median 9.2 vs 11.8 vs 13.0 months (mo), high vs low (as reference) logrank P = .0021) and OS (median 21.9 vs 35.8 vs 34.6 mo; logrank P = .0017) compared to APOE-median and -low, respectively. Opposite results were observed for DACH1, where DACH1-H tumors had longer PFS (median 14.5 vs 10.6 vs 8.07 mo; logrank P = .0011) and OS (median 39.4 vs 30.9 vs 21.5 mo; logrank P = .0021) when treated with cet. In bev-treated pts, similar results were observed with APOE-H showing shorter OS (median 25.8 vs 26.3 vs 37.5 mo; logrank P = .0016) and DACH1-H longer OS (median 36.5 vs 28.3 vs 22.4 mo; logrank P = .0017). No significant gene-treatment interaction was observed for either gene for PFS and OS. Conclusions: The tumor expression of metabolic genes associated with changes in the brain structure was prognostic in mCRC pts treated with first-line therapy. Notably, APOE and DACH1 have been recently reported to play a role in CRC where APOE overexpression has been associated with aggressive biological behavior whereas DACH1 has been shown to suppress CRC cell growth and invasion. Our results support this evidence and suggest that further investigation into the role of APOE and DACH1 in CRC biology and into their potential as targets for drug development is warranted. Trial Identifier: NCT00265850.
A world-wide study on delirium assessments and presence of protocols
Nydahl, Peter , Liu, Keibun , Bellelli, Giuseppe , Calle, Gabi Heras-La, Hoffmann, Magdalena , Jeitziner, Marie‐Madlen , Krewulak, Karla D. , Paulino, Maria Carolina , Haken, Rebecca von , Group, the WDAD Study, Abdalgany, Ahmed Gaber Ahmed, Aburaas, Amjad, Albakosh, Bashir Abobaker, Alhamdan, Hamza Ismail Ahmad, Aljbali, Akram Waled Rajab M, Al-Kandari, Fareeda, Anders, Daniel, Anderson, Marsali, Ashkenazy, Shelly , Avelino, Thiago, Bail, Kasia , Bakri, Ashraf , Baroum, Alaa Mohamed Ali , Brendt-Müller, Jennifer, Brobeil, Angelika, Byrnes, Tru , Cahill, Maria, Canelas, Maria Ana , Carroll, Ida, Conley, Amy, Cotton, Shannon A. , Couser, Mandy, Salgado, A., Cusworth, Elizabeth, Cvoro, Vera , Deosaran, Jordanna, Diebels, Merel, Docherty, Elaine A, Dossow, Vera von , Drennan, Megan, Egdeer, Akram Amin, Eichelsheim, Patrick, Elagili, Aissha Ali Saleh, Elsahl, Saifaleslam Jamal, Elshaikh, Hajer Alsadeg Mohammed, Fathi, Azza , Feige, Melanie, Fiest, Kirsten M. , Fong, Marleta Irene Joy, Fuchita, Mikita , Gaffney, Carol, Vich, Carola Giménez-Esparza, Feldmann, Nicole , Fitzpatrick, Neasa , Fong, Marleta Irene Joy, Goldberg, María Adela , Golüke, Nienke M.S. , Graaf, Marinette van der , Groenewald, Engelina , Gross, Renate , Segers, Camilla Grube, Hadi, Renate, Hamdan, Qusai Ahmad Hasan, Hamida, Bahaeddin Ben, Hamza, Monalyce, Hopkins, Jane , Hopkins, John , Jeyaseelan, Arveen , Kadhim, Ali Jawad, Kohler, S., Kooken, Rens , Khutwah, Ayman Salim Abu, Lange, Puck, Liefrink, Sharon, Lin, Yu‐Min , Loo, Shi Pei , Rodrigues, Sara Beatriz Lopes, MacDonald, Allan S., Madders, G, Massaro, Claudia, Maya, Kerri, Manioudaki, Sofia, Stewart, McKenna, Coimbra, Isabel , Miranda, Teresa, Mohamed, Mohamed A. , Mohammed, Mushin Mohammed Elhadi Agbna, Naeem, Fariha , Nam, Mi-Ryeo, Newman, Elaine, Nicol, Renae, Noonan, Claire, Lopes, Maria Inês, Otmani, Zina , O’Reilly, Susan, Ozorio, Valerie, Palakashappa, Jessica, Pandya, Tej , Papadea, Panagiota, Papanikolaou, Metaxia, Pinardi, Elena , Pereira, Inês Filipa Pinto, Premathilaka, Chirantha , Pop‐Purceleanu, Monica , Puchegger, Marlene, Qalhoud, Nouralddeen Mohammed, Raasing, Maike, Ragheb, Dalia Talaat, Ramadan, Nuri, Rubel, Mushabbir Hossain, Sainsbury, Kate, Schimböck, Florian , Schmädig, Roman , Schoon, Yvonne , Sethia, Deepak , Sextl, Edith, Shah, Bhagyesh , Shaout, Dua’a, Sharabi, Alaa Fouad, Shields, Lynn, Smith, Kendall A. , Dam, Linda Smulders-van, Soiza, Roy L. , Spiegler, Andrea, Stocks, Lucy, Sumerauer, Stefan, Tam, Stephanie , Tan, Aik Haw, Tohsche, Peter, Torres, Raquel Gouveia, Toth, Chantal, Tousgaard, Iben, Vogt, Birgit, Walsh, Erica M., Ward‐Stockham, Kristel , Mart, Melinda Webb‐St, Wijnen-Meijer, Mariajne Elisabeth, Zastrow, Inke , Nydahl, Peter , Jeitziner, Marie-Madlen , Krewulak, Karla D , Benbenishty, Julie Sarah , Boogaard, Mark van den , Caplan, Gideon A. , Chung, Chi Ryang , Elhadi, Muhammed , Gurjar, Mohan , Mailhot, Tanya , Morandi, Alessandro , Nawa, Ricardo Kenji , Oh, Esther S , Collet, Marie Oxenbøll , Lindroth, Heidi , Group, the WDAD Study, Abdelmohsen, Sarah Magdy , Aggar, Christina , Alkandari, Farah, Alkaseek, Akram Mohammed , Anders, Daniel, Anderson, Marsali, Blackwood, Bronagh , Brendt-Müller, Jennifer , Burke, Richard, Cacciatore, Stefano , Cahill, Maria, Conley, Amy, Costello, Maria , Diebels, Merel, Elshaikh, Hajer Alsadeg Mohammed, Emme, Christina , Exl, Matthias Thomas , Fong, Marleta Irene Joy, Gaffney, Carol, Fitzgerald, Rachel, Fong, Marleta Irene Joy, Graaf, Mirjam, Segers, Camilla Grube, Hadi, Renate, Hamdan, Qusai, Hetland, Breanna , Hopkins, Jane Adele, Ibrahim, Said A. , Imbrìaco, Guglielmo , Inoue, Shigeaki , Kadhim, Ali Jawad, Kohler, Sabrina, Korompeli, Anna , Krüger, Lars , Lange, Puck, Rodrigues, Sara Beatriz Lopes, MacDonald, Allan, McAndrew, Natalie S. , Mohamed, Mohamed Anwar Abdelsalam, Mohammed, Mushin Mohammed Elhadi Agbna, Mulkey, Malissa , Nakamura, Kensuke , Nam, Mi-Ryeo, Newman, Elaine, Nicol, Renae, Olotu, Cynthia , Ornago, Alice Margherita , O’Reilly, Susan, Penfold, Rose , Pereira, Inês Filipa Pinto, Quinn, Terence J , Raasing, Maike Wm, Rajhans, Prasad Anant , Ramadan, Nuri, Rubel, Mushabbir Hossain, Sainsbury, Kate, Salis, Francesco , Sharabi, Alaa Fouad, Smith, Kendall, Tam, Stephanie, Timmons, Suzanne , Torres, Raquel Gouveia, Tsolaki, Vasiliki , Castro, Roberta Esteves Vieira de , Vogt, Birgit, Walsh, Erica, Wefer, Franziska , Wøien, Hilde , Zazzara, Maria Beatrice

Mayo Clinic

Age and Ageing | June 12, 2024 | Volume: 53 | Issue: 7 | Pages: No page available

10.1093/ageing/afae129 | PMID 38952186 Get It

Abstract Background Delirium is a common complication of older people in hospitals, rehabilitation and long-term facilities. Objective To assess the worldwide use of validated delirium assessment tools and the presence of delirium management protocols. Design Secondary analysis of a worldwide one-day point prevalence study on World Delirium Awareness Day, 15 March 2023. Setting Cross-sectional online survey including hospitals, rehabilitation and long-term facilities. Methods Participating clinicians reported data on delirium, the presence of protocols, delirium assessments, delirium-awareness interventions, non-pharmacological and pharmacological interventions, and ward/unit-specific barriers. Results Data from 44 countries, 1664 wards/units and 36 048 patients were analysed. Validated delirium assessments were used in 66.7% (n = 1110) of wards/units, 18.6% (n = 310) used personal judgement or no assessment, and 10% (n = 166) used other assessment methods. A delirium management protocol was reported in 66.8% (n = 1094) of wards/units. The presence of protocols for delirium management varied across continents, ranging from 21.6% (on 21/97 wards/units) in Africa to 90.4% (235/260) in Australia, similar to the use of validated delirium assessments with 29.6% (29/98) in Africa to 93.5% (116/124) in North America. Wards/units with a delirium management protocol [n = 1094/1664, 66.8%] were more likely to use a validated delirium test than those without a protocol [odds ratio 6.97 (95% confidence interval 5.289–9.185)]. The presence of a delirium protocol increased the chances for valid delirium assessment and, likely, evidence-based interventions. Conclusion Wards/units that reported the presence of delirium management protocols had a higher probability of using validated delirium assessments tools to assess for delirium.
Long-term effect of increasing water intake on repeated self-assessed health-related quality of life (HRQoL) in autosomal dominant polycystic kidney disease
Rangan, Gopala K. , Allman‐Farinelli, Margaret , Boudville, Neil , Fernando, Mangalee, Haloob, Imad, Harris, David C.H. , Kumar, Karthik, Johnson, David W. , Lee, Vincent , Mai, Jun, Roger, Simon D. , Sagar, Priyanka S. , Sud, Kamal , Vilayur, Eswari, Rangan, Anna , Johnson, David W , Lee, Vincent W , Hawley, Carmel M. , Rangan, Anna , Torres, Vicente E.

Mayo Clinic

Clinical Kidney Journal | June 8, 2024 | Volume: 17 | Issue: 7 | Pages: No page available

10.1093/ckj/sfae159 | PMID 39165901 Get It

ABSTRACT Background The aim of this study was to determine the long-term effect of increasing water intake in patients with autosomal dominant polycystic kidney disease (ADPKD) on longitudinal changes in health-related quality of life (HRQoL) in the setting of a clinical trial. Methods Self-completed HRQoL (using the KDQoL-SF, v.1.3 questionnaire) was assessed annually in participants of a 3-year randomized controlled clinical trial (n = 187), allocated (1:1) either to increase water intake to reduce urine osmolality to ≤270 mosmol/kg (implemented by dietetic coaching, self-monitoring tools, text messaging) or continue usual water intake. Results Overall, 96% and 81.8% of participants (n = 187) completed the questionnaire at the baseline and final study visits, respectively. At baseline, the physical component summary score (PCS) and mental component summary score (MCS) were similar in the two groups (P > 0.05) and the five dimensions with the lowest scores in both groups were: energy and fatigue; general and overall health; sleep; emotional well-being; and pain. Within each group, there were no longitudinal changes over time. At the final visit, the PCS was higher in the increased water intake group (51.3 ± 7.6, mean ± standard deviation) compared to the usual water intake group 48.8 ± 9.3; P = 0.037) whereas the MCS was numerically similar. The improvement in the PCS was due to higher sub-scale values for physical functioning and pain (both P < 0.05). By multivariate analysis, only baseline PCS and height-corrected total kidney volume were associated with the final PCS (P < 0.05). Conclusion HRQoL scores remained stable over a 3 year period, and were not adversely affected by the intervention to increase water intake. Future studies should evaluate the clinical significance of the higher PCS in the increased water intake group.
Data driven discovery and quantification of hyperspectral leaf reflectance phenotypes across a maize diversity panel
Tross, Michael C. , Grzybowski, Marcin , Grove, Ryleigh J. , Nishimwe, Aime V. , Ganapathysubramanian, Baskar , Grzybowski, Marcin W , Jubery, Talukder Zaki , Torres‐Rodríguez, J. Vladimir , Sun, Guangchao , Ge, Yufeng , Schnable, James C

Mayo Clinic

The Plant Phenome Journal | June 7, 2024 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/ppj2.20106 Get It

Abstract Estimates of plant traits derived from hyperspectral reflectance data have the potential to efficiently substitute for traits, which are time or labor intensive to manually score. Typical workflows for estimating plant traits from hyperspectral reflectance data employ supervised classification models that can require substantial ground truth datasets for training. We explore the potential of an unsupervised approach, autoencoders, to extract meaningful traits from plant hyperspectral reflectance data using measurements of the reflectance of 2151 individual wavelengths of light from the leaves of maize ( Zea mays ) plants harvested from 1658 field plots in a replicated field trial. A subset of autoencoder‐derived variables exhibited significant repeatability, indicating that a substantial proportion of the total variance in these variables was explained by difference between maize genotypes, while other autoencoder variables appear to capture variation resulting from changes in leaf reflectance between different batches of data collection. Several of the repeatable latent variables were significantly correlated with other traits scored from the same maize field experiment, including one autoencoder‐derived latent variable (LV8) that predicted plant chlorophyll content modestly better than a supervised model trained on the same data. In at least one case, genome‐wide association study hits for variation in autoencoder‐derived variables were proximal to genes with known or plausible links to leaf phenotypes expected to alter hyperspectral reflectance. In aggregate, these results suggest that an unsupervised, autoencoder‐based approach can identify meaningful and genetically controlled variation in high‐dimensional, high‐throughput phenotyping data and link identified variables back to known plant traits of interest.
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2.
Millstein, Joshua , Yang, Yan , Algaze, Sandra, Ashouri, Karam , Mittal, Pooja, Torres‐Gonzalez, Lesly , Zhang, Wu, Höchster, Howard S. , Innocenti, Federico , Hashimoto, Tadayoshi , Lenz, Heinz‐Josef , Battaglin, Francesca , Soni, Shivani , Algaze, Sandra , Mittal, Pooja , Ou, Fang‐Shu , Venook, Alan P. , Mumenthaler, Shannon M. , Fujisawa, Takao , Nakamura, Yoshiaki , Bando, Hideaki , Yoshino, Takayuki

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3523-3523

10.1200/jco.2024.42.16_suppl.3523 Get It

3523 Background: Evidence suggests neurotransmitter signaling may play a crucial role in tumorigenesis of gastrointestinal (GI) cancers, including migration, proliferation, and apoptosis, as well as angiogenesis and the microenvironment. We developed and applied a strategy to identify upstream regulators of neurotransmitters and their associations with patient outcomes. Methods: Prior literature yielded 85 neurotransmitter signaling genes mapped to RNA-seq gene expression in tumor tissue from 545 patients with mCRC enrolled in the phase III CALGB/SWOG 80405 trial. These samples were also sequenced by FoundationOne CDx for DNA damage. Using Cox proportional hazards regression, we identified a subset of CDx genes associated with overall survival (OS) or progression-free survival (PFS). We extended the Causal Inference Test (CIT) for time-to-event data and identified a subset of the 85 signaling genes consistent with mediation of DNA mutation effects on OS and PFS. Another CIT analysis identified potential upstream neurotransmitter regulators, gene expression mediators of mutation effects on the signaling genes. Top genes were then assessed in whole-transcriptome sequencing (WTS) expression data with Caris MI profile collected from 398 patients with advanced CRC enrolled in the MONSTAR-SCREEN-2 trial. Results: At the 0.05 alpha level, we identified 20 signaling genes with gene expression associated with PFS and/or OS, and 68 genes with evidence of DNA mutations associated with PFS and/or OS. False discovery rate (FDR) < 0.05 was applied to filter the 56,674 expression features on PFS and OS associations, yielding 173 unique genes as possible mediators. The CIT yielded 53 putative mediators at FDR < 0.05, suggesting upstream regulation of neurotransmitter signaling. Five genes were identified as targeting at least 8 signaling genes each, PIGU, ANO9, LY6G6D, and GPR160, and FSCN1, where the first 4 are favorable and only FSCN1 is a poorer prognostic. Following up on these 5 genes in MONSTAR-SCREEN-2 by dichotomizing at the median value of WTS expression, 3 were nominally associated with OS, PIGU ( P = 0.050; HR, 0.59; 95%CI, 0.34-1.00), ANO9( P = 0.029; HR, 0.55; 95%CI, 0.32-0.95), LY6G6D( P = 0.0024; HR, 0.44; 95%CI, 0.25-0.76), and FSCN1 was suggestive ( P = 0.079; HR, 1.62; 95%CI, 0.94-2.77), with direction of effects in agreement with 80405 results for all four. Conclusions: Our novel approach identified previously unknown upstream regulators of neurotransmitter signaling associated with treatment outcomes in mCRC. PIGU, FSCN1, and LY6G6D have been suggested in prior literature as targets for CRC and ANO9 has been suggested as a target for GI cancer. These results bolster the strategy of using mediation analysis with large-scale molecular data to identify new therapeutic targets in CRC. NCT00265850.
Population‐level gene expression can repeatedly link genes to functions in maize
Torres‐Rodríguez, J. Vladimir , Li, Delin , Turkus, Jonathan , Newton, Linsey , Davis, J M , López‐Corona, Lina , Ali, Waqar , Sun, Guangchao , Mural, Ravi V. , Grzybowski, Marcin , Zamft, Bradley M., Thompson, Addie , Davis, Jensina , Grzybowski, Marcin W , Thompson, Addie M , Schnable, James C , Ali, Waqar

Mayo Clinic

The Plant Journal | May 30, 2024 | Volume: 119 | Issue: 2 | Pages: 844-860

10.1111/tpj.16801 | PMID 38812347 Get It

SUMMARY Transcriptome‐wide association studies (TWAS) can provide single gene resolution for candidate genes in plants, complementing genome‐wide association studies (GWAS) but efforts in plants have been met with, at best, mixed success. We generated expression data from 693 maize genotypes, measured in a common field experiment, sampled over a 2‐h period to minimize diurnal and environmental effects, using full‐length RNA‐seq to maximize the accurate estimation of transcript abundance. TWAS could identify roughly 10 times as many genes likely to play a role in flowering time regulation as GWAS conducted data from the same experiment. TWAS using mature leaf tissue identified known true‐positive flowering time genes known to act in the shoot apical meristem, and trait data from a new environment enabled the identification of additional flowering time genes without the need for new expression data. eQTL analysis of TWAS‐tagged genes identified at least one additional known maize flowering time gene through trans ‐eQTL interactions. Collectively these results suggest the gene expression resource described here can link genes to functions across different plant phenotypes expressed in a range of tissues and scored in different experiments.
Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer
Drew, David A. , Kim, Andre E. , Lin, Yi , Morrison, John L. , Lewinger, Juan Pablo , Fu, Yubo, Zemlianskaia, Natalia , Díez‐Obrero, Virginia , Baurley, James W. , Wu, Anna H. , Prentice, Ross L. , Harlid, Sophia , Barry, Elizabeth L. , Berndt, Sonja I. , Bouras, Emmanouil , Burnett‐Hartman, Andrea N. , Casey, Graham , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gruber, Stephen B. , Gsur, Andrea , Harrison, Tabitha A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Kundaje, Anshul , Li, Li , Newton, Christina C. , Obón‐Santacana, Mireia , Pai, Rish K. , Papadimitriou, Nikos , Scacheri, Peter C. , Schmit, Stephanie L. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Peters, Ulrike , Gauderman, W. James , Morrison, John L , Lewinger, Juan Pablo , Wang, Jun , Zemlianskaia, Natalia , Bien, Stephanie A , Dimou, Niki , Buchanan, Daniel D , Potter, John D , Prentice, Ross L , Harlid, Sophia , Arndt, Volker , Bouras, Emmanouil , Carreras-Torres, Robert , Casey, Graham , Devall, Matthew A M , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Kundaje, Anshul , Li, Li , Lynch, Brigid M , Nassir, Rami , Newton, Christina C , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Pardamean, Bens , Pellatt, Andrew J , Peoples, Anita R , Platz, Elizabeth A. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Su, Yu-Ru , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , Um, Caroline Y , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Hsu, Li , Moreno, Victor , Peters, Ulrike , Chan, Andrew T , Gauderman, W James , Drew, David A , Obón-Santacana, Mireia , Papadimitriou, Nikos , Diez-Obrero, Virginia , Qu, Conghui , Kawaguchi, Eric , Bien, Stephanie A. , Dimou, Niki , Albanes, Demetrius , Buchanan, Daniel D. , Potter, John D. , Arndt, Volker , Brenner, Hermann , Budiarto, Arif , Campbell, Peter T. , Carreras‐Torres, Robert , Conti, David V. , Gunter, Marc J. , Hidaka, Akihisa , Hoffmeister, Michael , Jenkins, Mark A. , Marchand, Loı̈c Le , Murphy, Neil , Nassir, Rami , Newcomb, Polly A. , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Stern, Mariana Carla , Tian, Yu , Tsilidis, Konstantinos K. , Ulrich, Cornelia M. , Um, Caroline Y. , White, Emily E. , Moreno, Vı́ctor , Chan, Andrew T.

Mayo Clinic

Science Advances | May 29, 2024 | Volume: 10 | Issue: 22 | Pages: No page available

10.1126/sciadv.adk3121 | PMID 38809988 Get It

Regular, long-term aspirin use may act synergistically with genetic variants, particularly those in mechanistically relevant pathways, to confer a protective effect on colorectal cancer (CRC) risk. We leveraged pooled data from 52 clinical trial, cohort, and case-control studies that included 30,806 CRC cases and 41,861 controls of European ancestry to conduct a genome-wide interaction scan between regular aspirin/nonsteroidal anti-inflammatory drug (NSAID) use and imputed genetic variants. After adjusting for multiple comparisons, we identified statistically significant interactions between regular aspirin/NSAID use and variants in 6q24.1 (top hit rs72833769 ), which has evidence of influencing expression of TBC1D7 (a subunit of the TSC1-TSC2 complex, a key regulator of MTOR activity), and variants in 5p13.1 (top hit rs350047 ), which is associated with expression of PTGER4 (codes a cell surface receptor directly involved in the mode of action of aspirin). Genetic variants with functional impact may modulate the chemopreventive effect of regular aspirin use, and our study identifies putative previously unidentified targets for additional mechanistic interrogation.
Whole-lung Lavage in a Patient with Pulmonary Alveolar Proteinosis
Guevara, Lindsay R Hunter, Gillespie, Shane M, Klompas, Alan M, Torres, Norman E, Barbara, David W, Klompas, Allan M. , Hunter Guevara, Lindsay R, Guevara, Lindsay R Hunter, Gillespie, Shane M, Torres, Norman E, Barbara, David W

Mayo Clinic

Annals of Cardiac Anaesthesia | May 28, 2024 | Volume: 21 | Issue: 2 | Pages: 215-217

10.4103/aca.aca_184_17 | PMID 29652291 Get It

Pulmonary alveolar proteinosis (PAP) is a rare syndrome in which phospholipoproteinaceous matter accumulates in the alveoli leading to compromised gas exchange. Whole-lung lavage is considered the gold standard for severe autoimmune PAP and offers favorable long-term outcomes. In this case report, we describe the perioperative management and procedural specifics of a patient undergoing WLL for PAP in which an anesthesiologist serves as the proceduralist and a separate anesthesiologist provides anesthesia care for the patient.
Implementation of a virtual community of practice to promote the empowerment of middle-aged people with multimorbidity: study protocol of a randomised controlled trial
Campillejo, Alba , Larrondo, Ileana Gefaell , Ramos‐García, Vanesa , Koatz, Débora , Santos-Álvarez, Anthea, Barrio-Cortés, Jaime , Gómez-Rueda, Sara, Calderón‐Larrañaga, Amaia , Garrido-Elustondo, Sofía, León, Beatriz González de , Ramón-Vazquez, José, Martín, Candelaria , Súarez-Fernández, Carmen, Parra-Caballero, Pedro, Quiroga-Colina, Patricia, Ramírez‐Puerta, Ana Belén, Tello-Bernabé, María-Eugenia, Sanchez-Gamborino, Estrella, Ugalde-Abiega, Beatriz, Vall‐Roqué, Helena , Abt-Sacks, Analía , Hernández-Yumar, Aránzazu , Muth, Christiane , Akker, Marjan van den , Orrego, Carola , González‐González, Ana Isabel , van den Akker, Marjan , Orrego, Carola , González-González, Ana Isabel , García, Alba Campillejo , Cifuentes, Patricia, Coello, Santiago Domínguez , García-García, Francisco Javier, Parra, Pedro , Vicente‐Rabaneda, Esther F. , Ruíz-López, Marta, Tello-Bernabé, María Eugenia, Ugalde-Abiega, Beatriz , Duarte‐Díaz, Andrea , Sacks, Analía Abt , Torres‐Castaño, Alezandra , Álvarez‐Pérez, Yolanda , Montori, Víctor M. , Perestelo‐Pérez, Lilisbeth

Mayo Clinic

BMJ Open | May 24, 2024 | Volume: 14 | Issue: 5 | Pages: e084937

10.1136/bmjopen-2024-084937 | PMID 38803252 Get It

Introduction Empowering people living with multimorbidity (multiple chronic conditions) to gain greater confidence in managing their health can enhance their quality of life. Education focused on self-management is a key tool for fostering patient empowerment and is mostly provided on an individual basis. Virtual communities of practice (VCoP) present a unique opportunity for online education in chronic condition self-management within a social context. This research aims to evaluate the effectiveness/cost-effectiveness of individualised, online self-management education compared with VCoP among middle-aged individuals living with multiple chronic conditions. Methods and analysis People aged 30–60, living with ≥2 chronic conditions and receiving care in primary care (PC) centres and outpatient hospital-based clinics in Madrid and Canary Islands will enrol in an 18-month parallel-design, blinded (intervention assessment and data analysts), pragmatic (adhering to the intention-to-treat principle), individually randomised trial. The trial will compare two 12-month web-based educational offers of identical content; one delivered individually (control) and the other with online social interaction (VCoP, intervention). Using repeated measures mixed linear models, with the patient as random effect and allocation groups and time per group as fixed effects, we will estimate between-arm differences in the change in Patient Activation Measure from baseline to 12 months (primary endpoint), including measurements at 6-month and 18-month follow-up. Other outcomes will include measures of depression and anxiety, treatment burden, quality of life. In addition to a process evaluation of the VCoP, we will conduct an economic evaluation estimating the relative cost-effectiveness of the VCoP from the perspectives of both the National Health System and the Community. Ethics and dissemination The trial was approved by Clinical Research Ethics Committees of Gregorio Marañón University Hospital in Madrid/Nuestra Señora Candelaria University Hospital in Santa Cruz de Tenerife. The results will be disseminated through workshops, policy briefs, peer-reviewed publications and local/international conferences. Trial registration number NCT06046326 .